Navigation Links
Dyadic International To Present At World Biofuels Markets
Date:3/4/2013

JUPITER, Fla., March 4, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, announced today that its President and CEO, Mark Emalfarb , will be making a presentation at the World Biofuels Markets exhibition at the Beurs-World Trade Center in Rotterdam, The Netherlands during its Advanced Biofuels Session: Transformative Technologies, at 4:00 p.m. local time on March 13, 2013.

(Logo:  http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

All attendees of the World Biofuels Markets are welcome to visit Dyadic's stand located at Booth #E506 where Dyadic's leading scientists will be available to discuss specific applications of Dyadic's AlternaFuel® CMAX™ biofuels enzymes.

The World Biofuels Markets is Europe's largest biofuels congress and exhibition and one of the industry's premier events, supporting the world's development and search for alternative energy sources.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International To Announce Year-End 2012 Financial Results And Host Conference Call On Thursday, March 7, 2013
2. Dyadic International Upgraded By OTC Markets To "Current Information" Tier
3. 12th U.S. Patent Issued To Dyadic International
4. Dyadic International Reports 2012 Third Quarter Financial Results
5. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
6. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
7. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
8. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
9. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
10. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
11. BioHealth Innovation, Inc. President & CEO Richard Bendis to Present at SXSW 2013 & 2013 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma ... its innovative TransCon technology to address significant unmet ... results for the full year ended December 31, ... year for our company as we broadened our ... leading, integrated rare disease company with an initial ...
(Date:3/22/2017)... 22, 2017   iSpecimen ┬«, the ... Doctors Pathology Service (DPS), a full-service anatomic pathology ... the United States , has joined a program ... Network (DHIN) to make human biospecimens and associated ... novel program, announced in 2015 as a collaboration between ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017   ... of next-generation cancer therapeutics designed to target cancer stemness ... Patricia S. Andrews as Chief Executive Officer, ... will succeed Chiang J. Li , M.D., FACP, ... company ten years ago. Under his leadership, Boston Biomedical ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is critical ... desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there is ... antibodies. , To meet this demand, the team at SCIEX has developed ...
Breaking Biology Technology:
(Date:2/28/2017)... February 28, 2017 News solutions for biometrics, ... ... from 14 to 16 March, Materna will present its ... how seamless travel is a real benefit for passengers. To ... to their passenger touch point solutions to take passengers through the ...
(Date:2/26/2017)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announces the appointment of ... "Too often, too many offenders return to jail ... trying to tackle this ongoing problem and improve ... members. While significant steps are underway, Securus continues to ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
Breaking Biology News(10 mins):